ZUG, Switzerland, July 25, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, ...

Boston Scientific ($BSX) announced an update on their ongoing clinical study. Study OverviewThis global Boston Scientific trial, officially titled ...

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma ...

Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutationPhase 2 results ...

Clinical trials continue to shape metastatic breast cancer treatment, making therapies safer, more tolerable, and more ...

Covariate-adaptive randomization represents an advanced methodology in the design of clinical trials, ensuring a balanced distribution of prognostic factors among treatment groups. This approach ...

The risk-based screening strategy was associated with similar detection rates for any cancer compared with annual screening ...

Immunome (IMNM) surges after positive phase 3 results for varegacestat in desmoid tumors. Read the latest analysis on the ...

Randomization Techniques (60 minutes): In this workshop, the rationale behind randomized experiments will be explained. Descriptions of commonly utilized randomization algorithms will be presented, ...

A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...

Patients undergoing cardiac surgery often receive red-cell transfusions, along with the associated risks and costs. Early intraoperative normovolemic hemodilution (i.e., acute normovolemic ...